EN DE

Imexpharm Corp (IMP) Fair Value & Analysis

Healthcare · VN · Market cap 6.0T VND · ISIN VN000000IMP0

What is Imexpharm Corp really worth?

IC Imexpharm Corp IMP · VN
Price38,900 VND
Fair Value33,097 VND
Upside−14.9%
Quality58/100

A solid business, but trading 18% above our fair value of 33,097 VND.

Watch Imexpharm Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Solidly profitable · 14.9% net margin
✓Low debt · generates free cash flow
✓Ranks above peers (10/14)

Risks

!Expensive Growth (revenue 5y +12.3 %/yr)
!Moderate moat 60/100
!The models disagree: range 19,217 VND to 61,534 VND
!Weak on valuation: 13 out of 100
!Weak on dividend: 22 out of 100
Evidence: High Range 19,217 VND – 61,534 VND

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 22 days ago

Fair value updated Aug 13, 2026, revised from 41,910 VND to 33,097 VND (−21.0%) since Jul 19, 2026. Share price +5.7% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The model range is unusually wide (19,217 VND to 61,534 VND). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

55,874 VND 18,349 VND Fair Value 33,097 VND May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 18,349 VND – 55,874 VND · fair‑value band 19,217 VND – 61,534 VND · the 38,900 VND price screens above the 33,097 VND fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Imexpharm Corp (IMP) currently trades at 38,900 VND, while our model-based Fair Value estimate is 33,097 VND, implying the stock looks roughly 17.5% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 44,548 VND per share, and 14 of the 26 models we run sit above the 38,900 VND price. Bear case: the Growth DCF group reads lowest at 4,964 VND, and 12 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Imexpharm Corp generated revenue of 2.4T VND at a net margin of 14.9%. Revenue declined 8.1% year over year. It earns a return on equity of 15.4%. Net debt stands at 23.6B VND. Fundamentals as of Aug 13, 2026

Our scenario range runs from 19,217 VND (bear case) to 61,534 VND (bull case); at 38,900 VND, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 32% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −15%, IMP screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 1,367 VND per share, which is 4.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF best evidence 3,008 VND 5,124 VND 9,001 VND 78
Growth DCF 2,995 VND 4,964 VND 8,532 VND 76
EPV 27,374 VND 32,103 VND 36,306 VND 74
All 26 models by family
DCF Models
FCF DCF best evidence 3,008 VND 5,124 VND 9,001 VND 78
Owner Earnings 38,575 VND 71,684 VND 132,330 VND 73
5Y Revenue Exit 20,154 VND 40,458 VND 69,001 VND 70
5Y EBITDA Exit 26,195 VND 52,966 VND 87,447 VND 73
5Y P/E Exit 25,384 VND 51,286 VND 81,569 VND 69
10Y Revenue Exit 13,657 VND 31,472 VND 60,520 VND 63
10Y EBITDA Exit 18,746 VND 40,873 VND 76,388 VND 64
10Y P/E Exit 18,194 VND 39,610 VND 71,331 VND 61
Earnings-Based
Graham-Dodd 15,416 VND 72,528 VND 99,713 VND 64
Lynch FV 19,217 VND 27,453 VND 35,689 VND 61
PEG = 1.0 19,217 VND 27,453 VND 35,689 VND 57
EPV 27,374 VND 32,103 VND 36,306 VND 74
Dividend Discount
Gordon GGM 4,810 VND 10,500 VND 17,667 VND 65
DDM Multi-Stage 4,810 VND 8,601 VND 10,943 VND 66
Multiples
P/E Multiple 37,405 VND 49,874 VND 62,342 VND 63
P/S Multiple 28,904 VND 38,539 VND 48,174 VND 58
P/B Multiple 28,904 VND 38,539 VND 48,174 VND 55
EV/EBIT 38,863 VND 51,624 VND 64,386 VND 66
EV/EBITDA 39,246 VND 52,136 VND 65,025 VND 67
EV/Revenue 27,903 VND 39,614 VND 51,324 VND 53
Asset-Based
NCAV (Graham) 7,488 VND 10,034 VND 14,977 VND 54
Growth DCF
Growth DCF 2,995 VND 4,964 VND 8,532 VND 76
Rev-Margin DCF 20,154 VND 39,419 VND 64,341 VND 70
Economic Profit
Residual Income 15,702 VND 20,952 VND 66,940 VND 64
ROIC Compounder 31,408 VND 43,298 VND 59,438 VND 71
Growth Earnings
Growth-Adj P/E 31,183 VND 44,548 VND 57,912 VND 67

Widest divergence: Growth Earnings (44,548 VND) versus Growth DCF (4,964 VND). Highest evidence: FCF DCF (78).

Notify me when IMP reaches fair value

Put IMP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 19.3
P/S ratio 2.76 P/E × margin
EPS (TTM) 2,018 VND price ÷ EPS = P/E 19.3
Dividend yield 1.1% payout 21.2%
Net margin 14.3% FY2025
Return on equity 15.4% TTM
More key figures
Profitability
Return on assets (EBIT) 14.5% avg 5y
Operating margin 19.0% TTM
Growth
Revenue (TTM) 2.4T VND TTM
Revenue growth (YoY) −8.1% 3y avg +14.1%
EPS growth (YoY) +10.2%
Balance sheet & cash flow
Free cash flow 27.3B VND FY2025
Net debt 23.6B VND FY2025 · ≈ 0.9 yrs of FCF

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 58/100

Of which business quality 55 · Market factors (momentum, volatility) 33

Profitability 65
Margins and returns on capital today
Quality Growth 56
Are margins and returns improving?
Cashflow 17
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 77
Disciplined investing over empire-building
Low Volatility 90
Calm price path (market factor)
Momentum 12
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 40
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, …

Full company description

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietnam. As of April 29, 2026, Imexpharm Corporation operates as a subsidiary of Livzon Pharmaceutical Group Inc..

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Imexpharm Corp reported revenue of 2.4T VND in FY2025 versus 1.3T VND in FY2021, a compound +17.8%/yr. Reported net income was 349B VND in FY2025, compounding +16.6%/yr from FY2021.

Growth Quality 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
2.4T VND
Latest YoY
+10.7%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+14.1%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+12.3%
Avg. revenue growth/yr (6Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+9.7%
Value creation/yr (5Y, in VND) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year. Measured in VND: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.3% (−4.4 + 1.1)
Revenue +17.8%/yr
FY21 1.3T VND
FY22 1.6T VND
FY23 2.0T VND
FY24 2.2T VND
FY25 2.4T VND
Net income +16.6%/yr
FY21 189B VND
FY22 224B VND
FY23 300B VND
FY24 321B VND
FY25 349B VND

IMP screens 18% overvalued. Compare with Merck KGaA →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Imexpharm Corp · Fair Value
33,097 VND −18%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Imexpharm Corp Fair Value". https://www.fairvalue-calculator.com/stock/IMP

Peer Group

Drug Manufacturers - Specialty & Generic · 608 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 58 · Above median
Fair Value upside −15% · Above median
Return on equity (TTM) 15% · Top 25%
Return on assets 10% · Top 25%
Net margin (TTM) 15% · Top 25%
Operating margin (TTM) 19% · Top 25%
Revenue growth −8% · Bottom 25%
Dividend yield (TTM) 1.1% · Below median
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 19.3× · Cheaper than median
P/B 2.61× · Pricier than median
P/S (TTM) 2.52× · Pricier than median
P/FCF 0.0× · Cheaper than 75% of peers
EV/EBITDA 10.4× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE13 · sector 2
FUTURE0 · sector 22
PAST62 · sector 26
HEALTH98 · sector 97
DIVIDEND22 · sector 29

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €140.25 €106.48 −24%
Takeda Pharmaceutical Company TAK $18.03 $11.11 −38%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 −52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 −49%
Galderma Group GALD CHF 178.55 CHF 55.07 −69%
Haleon plc HLN $10.11 $7.64 −24%
Teva Pharmaceutical Industries Limited TEVA $36.05 $15.33 −57%
Sandoz Group SDZ CHF 70.66 CHF 39.21 −45%
Zoetis Inc ZTS $77.10 $104.88 +36%
Hansoh Pharmaceutical Group 3692 HK$35.12 HK$16.18 −54%

Compare Imexpharm Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Imexpharm Corp (IMP) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 33,097 VND versus a price of 38,900 VND, about −15% upside (overvalued).
What is the fair value of IMP?
Our model-based fair value for Imexpharm Corp is 33,097 VND (as of Aug 13, 2026), built from audited fundamentals. The current price: 38,900 VND.
What is the quality score of IMP?
Imexpharm Corp has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Imexpharm Corp (IMP)?
Imexpharm Corp reported trailing-twelve-month revenue of about 2.4T VND (latest available figure, as of Aug 13, 2026).
What is the net profit margin of IMP?
The net profit margin of Imexpharm Corp is about 14.9%, meaning it keeps roughly 14.9% of revenue as net income. Based on the latest reported figures.
Does Imexpharm Corp pay a dividend?
Imexpharm Corp currently shows a dividend yield of about 1.10% relative to its recent price (as of Aug 13, 2026).
Free · no account needed

Watch Imexpharm Corp in the live analysis

One click puts Imexpharm Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.